A recent manufacturing plant visit by brokerage firm Anand Rathi to Jubilant Ingrevia’s (JUBLINGR) Bharuch site has strongly reinforced conviction in the company’s growth trajectory. With key headwinds fading and large-scale projects coming online, Fiscal Year 2027 (FY27) is shaping up to be a definitive earnings inflection year for the specialty chemicals player.
Underpinned by strong management guidance and a robust contract manufacturing pipeline, Anand Rathi has maintained its BUY rating on the stock with a Sum-of-the-Parts (SOTP) based target price of ₹975.
Key Operational and Financial Highlights
- Upward EBITDA Guidance: Jubilant Ingrevia’s management has guided for FY27 EBITDA at the upper end of ₹7.5 billion to ₹8.0 billion (compared to approximately ₹6.0 billion in FY26). This implies an operating EBITDA of around ₹7.6 billion, outperforming Anand Rathi’s conservative estimate of ₹7.3 billion.
- Strong Earnings Growth: The company is projected to clock a massive 32% earnings Compound Annual Growth Rate (CAGR) over the FY26–FY28e period.
- Segment Drivers: The Specialty Chemicals and Nutrition & Health Solutions (NHS) segments are expected to be the primary engines of growth, contributing more than 85% of the incremental EBITDA.
Overhang Eases as Customer Bankruptcy Risks Recede
One of the most significant structural positives for Jubilant Ingrevia is the easing of a major project overhang. Concerns regarding the financial health of the company’s key innovator partner have largely alleviated. The innovator has successfully executed $966 million in cash actions against its $1.0 billion 2026 deleveraging target. This massive debt-reduction effort has effectively eliminated immediate bankruptcy concerns, stabilizing the long-term outlook for Jubilant’s contracted projects.
Agro CDMO Commissioned with Secure Cash Flows
Jubilant’s highly anticipated Agro CDMO (Contract Development and Manufacturing Organization) plant is now fully commissioned and actively producing.
While near-term volume visibility remains somewhat limited due to a sluggish global agribusiness demand environment and ongoing input cost pressures, Jubilant’s downside is strictly protected. The asset’s EBITDA is entirely ring-fenced under a rigid 5-year take-or-pay structure, guaranteeing steady cash flows regardless of immediate macro volatility.
A Deep CDMO Pipeline and Commodity Tailwinds
Beyond the primary anchor agro contract, Jubilant Ingrevia is rapidly scaling its broader custom manufacturing footprint:
- Pipeline Scope: The CDMO pipeline currently boasts over 100 molecules in development.
- Near-Term Revenue: This includes 20 confirmed commercial opportunities that hold an estimated revenue potential of approximately ₹15 billion.
- Long-Term Scaling: Overall CDMO revenue is projected to scale to roughly ₹12 billion by FY28.
Simultaneously, the company is benefiting from incremental macro tailwinds. An improving product mix in the Nutrition segment and a sharp recovery in Acetic Acid prices—which have rebounded from historical lows of around $300/ton to approximately $450/ton—are expected to provide a healthy boost to the legacy segments’ margins.
The Bottom Line
With major capital expenditures transitioning into revenue-generating assets, a de-risked customer profile, and a protected downside via take-or-pay agreements, Jubilant Ingrevia appears fundamentally well-positioned. Anand Rathi’s target price of ₹975 reflects strong confidence that the company will successfully capture high-margin specialty market shares over the next two fiscal years.